These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
462 related articles for article (PubMed ID: 20864916)
1. Phase II trial of FOLFOX6, bevacizumab, and cetuximab in the first-line treatment of metastatic colorectal cancer. Spigel DR; Greco FA; Waterhouse D; Shipley D; Lane CM; Vazquez ER; Clark BL; Infante JR; Bendell JC; Burris HA; Hainsworth JD Clin Adv Hematol Oncol; 2010 Jul; 8(7):480-5, 498. PubMed ID: 20864916 [TBL] [Abstract][Full Text] [Related]
2. A phase II trial of FOLFOX6 and cetuximab in the first-line treatment of patients with metastatic colorectal cancer. Boccia RV; Cosgriff TM; Headley DL; Badarinath S; Dakhil SR Clin Colorectal Cancer; 2010 Apr; 9(2):102-7. PubMed ID: 20378504 [TBL] [Abstract][Full Text] [Related]
3. Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer. Saltz L; Badarinath S; Dakhil S; Bienvenu B; Harker WG; Birchfield G; Tokaz LK; Barrera D; Conkling PR; O'Rourke MA; Richards DA; Reidy D; Solit D; Vakiani E; Capanu M; Scales A; Zhan F; Boehm KA; Asmar L; Cohn A Clin Colorectal Cancer; 2012 Jun; 11(2):101-11. PubMed ID: 22055112 [TBL] [Abstract][Full Text] [Related]
4. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III). Schmoll HJ; Cunningham D; Sobrero A; Karapetis CS; Rougier P; Koski SL; Kocakova I; Bondarenko I; Bodoky G; Mainwaring P; Salazar R; Barker P; Mookerjee B; Robertson J; Van Cutsem E J Clin Oncol; 2012 Oct; 30(29):3588-95. PubMed ID: 22965961 [TBL] [Abstract][Full Text] [Related]
5. Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. Tabernero J; Van Cutsem E; Díaz-Rubio E; Cervantes A; Humblet Y; André T; Van Laethem JL; Soulié P; Casado E; Verslype C; Valera JS; Tortora G; Ciardiello F; Kisker O; de Gramont A J Clin Oncol; 2007 Nov; 25(33):5225-32. PubMed ID: 18024868 [TBL] [Abstract][Full Text] [Related]
6. [Clinical significance of bolus 5-fluorouracil for recurrent or metastatic colorectal cancer treated with FOLFOX+ BevacizumabTherapy]. Yoshida Y; Hasegawa J; Nishimura J; Hirota M; Kim Y; Nezu R Gan To Kagaku Ryoho; 2011 Aug; 38(8):1293-6. PubMed ID: 21829066 [TBL] [Abstract][Full Text] [Related]
7. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial. Hegewisch-Becker S; Graeven U; Lerchenmüller CA; Killing B; Depenbusch R; Steffens CC; Al-Batran SE; Lange T; Dietrich G; Stoehlmacher J; Tannapfel A; Reinacher-Schick A; Quidde J; Trarbach T; Hinke A; Schmoll HJ; Arnold D Lancet Oncol; 2015 Oct; 16(13):1355-69. PubMed ID: 26361971 [TBL] [Abstract][Full Text] [Related]
8. Oxaliplatin in combination with infusional 5-fluorouracil as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumors. Benavides M; Pericay C; Valladares-Ayerbes M; Gil-Calle S; Massutí B; Aparicio J; Dueñas R; González-Flores E; Carrato A; Marcuello E; Gómez A; Cabrera E; Queralt B; Gómez MJ; Guasch I; Etxeberría A; Alfaro J; Campos JM; Reina JJ; Aranda E Clin Colorectal Cancer; 2012 Sep; 11(3):200-6. PubMed ID: 22421001 [TBL] [Abstract][Full Text] [Related]
9. Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: a Gruppo Oncologico dell'Italia Meridionale Multicenter phase II study. Colucci G; Giuliani F; Garufi C; Mattioli R; Manzione L; Russo A; Lopez M; Parrella P; Tommasi S; Copetti M; Daniele B; Pisconti S; Tuveri G; Silvestris N; Maiello E Oncology; 2010; 79(5-6):415-22. PubMed ID: 21474966 [TBL] [Abstract][Full Text] [Related]
10. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Heinemann V; von Weikersthal LF; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Hielscher J; Scholz M; Müller S; Link H; Niederle N; Rost A; Höffkes HG; Moehler M; Lindig RU; Modest DP; Rossius L; Kirchner T; Jung A; Stintzing S Lancet Oncol; 2014 Sep; 15(10):1065-75. PubMed ID: 25088940 [TBL] [Abstract][Full Text] [Related]
11. Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients: phase II study. Santini D; Vincenzi B; Schiavon G; Di Seri M; Virzí V; Spalletta B; Caricato M; Coppola R; Tonini G Cancer Chemother Pharmacol; 2007 Apr; 59(5):613-20. PubMed ID: 16944151 [TBL] [Abstract][Full Text] [Related]
12. A phase 1B study of dulanermin in combination with modified FOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer. Wainberg ZA; Messersmith WA; Peddi PF; Kapp AV; Ashkenazi A; Royer-Joo S; Portera CC; Kozloff MF Clin Colorectal Cancer; 2013 Dec; 12(4):248-54. PubMed ID: 24075777 [TBL] [Abstract][Full Text] [Related]
13. Sorafenib in combination with oxaliplatin, leucovorin, and fluorouracil (modified FOLFOX6) as first-line treatment of metastatic colorectal cancer: the RESPECT trial. Tabernero J; Garcia-Carbonero R; Cassidy J; Sobrero A; Van Cutsem E; Köhne CH; Tejpar S; Gladkov O; Davidenko I; Salazar R; Vladimirova L; Cheporov S; Burdaeva O; Rivera F; Samuel L; Bulavina I; Potter V; Chang YL; Lokker NA; O'Dwyer PJ Clin Cancer Res; 2013 May; 19(9):2541-50. PubMed ID: 23532888 [TBL] [Abstract][Full Text] [Related]
14. A phase I/II study of capecitabine given on a week on/week off schedule combined with bevacizumab and oxaliplatin for patients with untreated advanced colorectal cancer. Sehgal R; Lembersky BC; Rajasenan KK; Crandall TL; Balaban EP; Pinkerton RA; Kane P; Schmotzer A; Zeh H; Potter DM; Ramanathan RK Clin Colorectal Cancer; 2011 Jun; 10(2):117-20. PubMed ID: 21859564 [TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of modified FOLFOX6 plus high-dose bevacizumab in second-line or later treatment of patients with metastatic colorectal cancer. Takii Y; Maruyama S Chemotherapy; 2013; 59(2):79-84. PubMed ID: 23881273 [TBL] [Abstract][Full Text] [Related]
17. [Efficacy and safety of bevacizumab (BEV) plus chemotherapeutic agents in the treatment of metastatic colorectal cancer, mCRC]. Guo X; Liu TS; Yu YY; Zhou YH; Chen Y; Zhuang RY; Cui YH Zhonghua Zhong Liu Za Zhi; 2013 Aug; 35(8):604-7. PubMed ID: 24314219 [TBL] [Abstract][Full Text] [Related]
18. Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study. Soda H; Maeda H; Hasegawa J; Takahashi T; Hazama S; Fukunaga M; Kono E; Kotaka M; Sakamoto J; Nagata N; Oba K; Mishima H BMC Cancer; 2015 Oct; 15():695. PubMed ID: 26467662 [TBL] [Abstract][Full Text] [Related]
19. Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II). Hoff PM; Hochhaus A; Pestalozzi BC; Tebbutt NC; Li J; Kim TW; Koynov KD; Kurteva G; Pintér T; Cheng Y; van Eyll B; Pike L; Fielding A; Robertson JD; Saunders MP J Clin Oncol; 2012 Oct; 30(29):3596-603. PubMed ID: 22965965 [TBL] [Abstract][Full Text] [Related]
20. A phase II study of bevacizumab, oxaliplatin, and capecitabine in patients with previously untreated metastatic colorectal cancer: a prospective, multicenter trial of the Korean Cancer Study Group. Hong YS; Lee SS; Kim KP; Lee JL; Kang YK; Shin SJ; Ahn JB; Jung KH; Im SA; Kim TY; Kim JH; Park YS; Kim TW Am J Clin Oncol; 2014 Feb; 37(1):19-23. PubMed ID: 23111359 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]